Press Release

EHSI Weighing Placement Options for NASA Bioreactor

By SpaceRef Editor
January 3, 2011
Filed under , ,

Emerging Healthcare Solutions (PinkSheets:EHSI) President and CEO Cindy Morrissey said today that the company is in discussions with its wholly owned subsidiary, Celulas Genetica, to determine the initial placement of their recently acquired NASA-developed bioreactor.

“Currently, EHSI is making plans to train laboratory technicians and other personnel here in the U.S. to use the NASA bioreactor”

NASA’s IntrifugeRotary Cell Culture SystemTM is a rotating-wall bioreactor originally designed to facilitate the growth of human cells in simulated weightlessness. Cell cultures–including stem cells–grown inside the bioreactor look and function much closer to human cells grown within the body than cell cultures grown in Petri dishes.

Last week, EHSI acquired a license to use the bioreactor to expand adult stem cells in China, Panama, and elsewhere around the globe. Stem cell expansion is essential to the research planned by Celulas Genetica, including its current endeavor to develop a revolutionary new cure for liver disease known as the Rutherford Procedure.

“Currently, EHSI is making plans to train laboratory technicians and other personnel here in the U.S. to use the NASA bioreactor,” Morrissey said. “When our company has fully familiarized itself with this technology and its potential uses, we plan to send the bioreactor to Panama, China or another location outside the U.S. for use by Celulas Genetica in developing its treatment for liver disease. Discussions with Celulas Genetica regarding prime placement options for the device are ongoing.”

The expansion of stem cells is crucial to the success of the Rutherford Procedure, a groundbreaking organ regeneration treatment being developed to utilize proton-beam technology to destroy diseased organ tissue for regeneration. During the procedure, proton therapy will be used to destroy scar-tissue cells in the liver using high-energy proton beams, a non-invasive treatment proven to minimize damage to healthy tissues and to eliminate the side effects of traditional radiation therapy.

As the scar tissue is systematically destroyed by the proton therapy, a catheter will deliver the patient’s own cultured stem cells directly to the patient’s liver through the bloodstream. As more and more diseased tissue is destroyed, these cultured stem cells could help regenerate the patient’s damaged, cirrhotic liver into a healthy, functioning organ once more.

Celulas Genetica purchased a license to develop and market the Rutherford Procedure in December. Celulas Genetica is only the latest outpost in Emerging Healthcare Solutions’ global footprint. In addition to its Houston headquarters, the company also maintains business offices in Frankfurt, Germany and Warsaw, Poland.

EHSI invests in technology developed to compete in the stem-cell research industry alongside Amgen (NASDAQ:AMGN), Dendreon Corporation (NASDAQ:DNDN), Smith & Nephew (NYSE:SNN) and Pharmaceutical Product Development (NASDAQ:PPDI).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.

For more information, please visit

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Emerging Healthcare Solutions, Inc.
Cindy Morrissey, 713-821-1486
President and CEO

SpaceRef staff editor.